ArticleInfection and drug resistance2025
Epidemiological Trends and Drug Resistance Patterns of Carbapenem-Resistant Gram-Negative Bacteria: A Retrospective Study in a Tertiary Hospital in China (2019-2024).
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Molecular characteristics and analysis of drug resistance-virulence correlation of carbapenem-resistantMicrobiology spectrum · 2026Article
- Prevalence, antimicrobial resistance, and associated factors of critical superbugs Klebsiella pneumoniae and Acinetobacter species among hospitalized patients in Northwest Ethiopia.BMC microbiology · 2026Article
- Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.BMC infectious diseases · 2026Article
- Evolution in Epidemiology and Antimicrobial Resistance Patterns of Bacteria Among Dermatology Patients: A Retrospective Study in a Tertiary Dermatology Hospital in China (2018-2023).Infection and drug resistance · 2026Article
- Comparative genomic insights into carbapenem-resistant versus susceptibleFrontiers in cellular and infection microbiology · 2026Article
- Efficacy and safety of ceftazidime-avibactam in carbapenem-resistant gram-negative bacilli sepsis according to infection site.American journal of translational research · 2026Article
- The efficacy and safety of colistimethate sodium in the treatment of carbapenem-resistant Gram-negative bacilli: a real-world observational study.Frontiers in cellular and infection microbiology · 2026Observational
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To elucidate the distribution characteristics and drug resistance of carbapenem-resistant gram-negative bacteria (CR-GNB) within a general hospital setting from 2019 to 2024. Methods: The distribution characteristics of CR-GNB and antimicrobial resistance patterns among inpatients from 2019 to 2024 were investigated. The detection rate, departmental distribution, annual trends, and drug susceptibility profiles of key carbapenem-resistant bacterial species were compared. Results: A total of 34, 370 patients infected with GNB were investigated, with 2967 cases identified as CR-GNB. Among these, the nosocomial infection rate of carbapenem-resistant Conclusion: The detection of CR-GNB in this hospital from 2019 to 2024 indicates a widespread distribution across clinical departments and infection sites, coupled with a high rate of resistance to commonly used antimicrobials. Local hospitals should prioritize the distribution patterns of CR-GNB to develop personalized prevention strategies, strengthen hospital public health and infection prevention and control measures, and promote rational use of antibiotics to effectively curb the spread of CR-GNB infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.